Efficacy and Safety of Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Results from BE VIVID, a 52-Week Phase 3, Randomized, Double-Blinded, Ustekinumab- and Placebo-Controlled Study. J of Skin [Internet]. 2020 Oct. 27 [cited 2025 Apr. 19];4(6):s82. Available from: https://skin.dermsquared.com/skin/article/view/1115